Haemonetics CorporationHAENYSE
Loading
EV/EBITDA Over TimeContracting
Percentile Rank14
3Y CAGR-16.2%
5Y CAGR-11.1%
Studio
Year-over-Year Change

Enterprise value to EBITDA ratio

3Y CAGR
-16.2%/yr
vs -6.6%/yr prior
5Y CAGR
-11.1%/yr
Recent deceleration
Acceleration
-9.6pp
Decelerating
Percentile
P14
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
4 yr
Consecutive declineContracting
PeriodValueYoY Change
202511.51-31.0%
202416.68-10.2%
202318.59-4.9%
202219.55-42.0%
202133.70+62.3%
202020.77-16.6%
201924.91-3.1%
201825.70+39.9%
201718.38+14.1%
201616.11-